2025年全球医药行业收购活动活跃,又一家跨国药企发起“补强型并购“!

制药网
18 Jul

【制药网 行业动态】近日,美国天境生物(I-Mab,NASDAQ:IMAB)宣布达成最终协议,通过全资收购Bridge Health Biotech公司,进一步巩固其在肿瘤免疫治疗领域特别是CLDN18.2靶点上的竞争优势。根据协议条款,天境生物将向Bridge Health股东支付180万美元的首付款,并在2027年前完成总计120万美元的非或有付款(assured payments)。此外,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10